Page last updated: 2024-11-12

6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID9936746
CHEMBL ID3581647
CHEBI ID191051
SCHEMBL ID2898131

Synonyms (59)

Synonym
birabresib
bdbm50092312
otx-015 ,
mk-8628
202590-98-5
CHEBI:191051
2-[(9s)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]-n-(4-hydroxyphenyl)acetamide
6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-
otx015 ,
S7360 ,
CS-1598
HY-15743
SCHEMBL2898131
(s)-n-(4-hydroxyphenyl)-4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide
GNMUEVRJHCWKTO-FQEVSTJZSA-N
(6s)-4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetamide
6h-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetamide, 4-(4-chlorophenyl)-n-(4-hydroxyphenyl)-2,3,9-trimethyl-, (6s)-
birabresib [usan]
unii-x40lks49s3
x40lks49s3 ,
otx-015 anhydrous
otx 015
(s)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(4-hydroxyphenyl)acetamide
2-[(6s)-4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f]-[1, 2, 4] triazolo [4,3-a] [1, 4] diazepin-6-yl]-n-(4-hydroxyphenyl)-acetamide dehydrate
gtpl8359
otx015 anhydrous
y-803 anhydrous
CHEMBL3581647
2-((6s)-4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno(3,2- f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)- n-(4-hydroxyphenyl)acetamide
birabresib [who-dd]
birabresib [inn]
J-690257
EX-A640
AKOS027323345
(s)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(4-hydroxyphenyl)acetamide, aldrichcpr
otx015 pound mk 8628/birabresib pound(c)
otx015, >=98% (hplc)
D10911
birabresib (usan/inn)
mfcd26960949
NCGC00356067-01
(s)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]-triazolo[4,3-a][1,4]diazepin-6-yl)-n-(4-hydroxyphenyl)acetamide
otx015 (birabresib)
(s)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-n-(4-hydroxyphenyl)acetamide.
mk-8628;birabresib
DB15189
Q27075296
2-[(6s)-4-(4-chlorophenyl)-2,3,9-trimethyl-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-n-(4-hydroxyphenyl)acetamide
6je ,
CCG-264724
NCGC00356067-12
nsc-778747
nsc778747
BP-25368
GS-9310
2-[(9s)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0(2),?]trideca-2(6),4,7,10,12-pentaen-9-yl]-n-(4-hydroxyphenyl)acetamide
O0482
DTXSID701103937
AC-35281

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" We characterized the pharmacokinetics of this first-in-class BET-BRD inhibitor administered as a single agent, including population pharmacokinetic modelling."( Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Bekradda, M; Bourdel, F; Cunningham, D; Cvitkovic, E; Herait, P; Kahatt, C; Lokiec, F; Odore, E; Quesnel, B; Raffoux, E; Rezaï, K; Riveiro, ME; Stathis, A; Thieblemont, C, 2016
)
0.43
" Five or eight blood samples were collected per patient for pharmacokinetic analysis."( Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Bekradda, M; Bourdel, F; Cunningham, D; Cvitkovic, E; Herait, P; Kahatt, C; Lokiec, F; Odore, E; Quesnel, B; Raffoux, E; Rezaï, K; Riveiro, ME; Stathis, A; Thieblemont, C, 2016
)
0.43
" The estimated pharmacokinetic parameters were the absorption rate constant (k a) = 0."( Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Bekradda, M; Bourdel, F; Cunningham, D; Cvitkovic, E; Herait, P; Kahatt, C; Lokiec, F; Odore, E; Quesnel, B; Raffoux, E; Rezaï, K; Riveiro, ME; Stathis, A; Thieblemont, C, 2016
)
0.43
" Population pharmacokinetic modelling of OTX015 plasma concentrations showed that LBM influences V and CL."( Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Bekradda, M; Bourdel, F; Cunningham, D; Cvitkovic, E; Herait, P; Kahatt, C; Lokiec, F; Odore, E; Quesnel, B; Raffoux, E; Rezaï, K; Riveiro, ME; Stathis, A; Thieblemont, C, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" We investigated the pharmacologic characteristics of OTX015 as a single agent and combined with targeted therapy or conventional chemotherapies in glioblastoma cell lines."( OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Astorgues-Xerri, L; Bekradda, M; Berenguer-Daizé, C; Cayol, M; Cvitkovic, E; Lokiec, F; MacKenzie, S; Noel, K; Odore, E; Ouafik, L; Rezai, K; Riveiro, ME, 2016
)
0.43
" Here, we report in vivo data for OTX015 in combination with the histone deacetylase inhibitor vorinostat, the Bruton's tyrosine kinase inhibitor ibrutinib, the anti-CD20 monoclonal antibody rituximab, and the mTOR inhibitor everolimus in a diffuse large B cell lymphoma model."( Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Bernasconi, E; Bertoni, F; Cascione, L; Cvitkovic, E; Gaudio, E; Odore, E; Ponzoni, M; Rezai, K; Rinaldi, A; Riveiro, E; Stathis, A; Tarantelli, C; Zucca, E, 2016
)
0.43
" The aim of this study was to evaluate the anti-tumor activity of OTX015 as single agent and in combination with everolimus in TNBC models."( The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Astorgues-Xerri, L; Bekradda, M; Beltrame, L; Bertoni, F; Cvitkovic, E; D'Incalci, M; Erba, E; Frapolli, R; Kwee, I; Odore, E; Panini, N; Rezai, K; Rinaldi, A; Riveiro, ME; Vázquez, R, 2017
)
0.46
" Our data provide a landscape of drug combination effects in BL and suggest that targeting CDK and BET could provide a novel vulnerability of BL."( Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma.
Brors, B; Huber, W; Hüllein, J; Kurilov, R; Lee, KS; Lukas, M; Oleś, M; Sellner, L; Tomska, K; Wagner, L; Walther, T; Zenz, T, 2018
)
0.48
" MYC/MYCN and MDM2 have been shown to interact and contribute to NB growth and disease progression."( The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Bond, J; Goodyke, A; Kelly, S; Maser, T; Nagulapally, A; Ostrander, A; Park, Y; Saulnier Sholler, G; Zagorski, J, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The estimated pharmacokinetic parameters were the absorption rate constant (k a) = 0."( Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies.
Bekradda, M; Bourdel, F; Cunningham, D; Cvitkovic, E; Herait, P; Kahatt, C; Lokiec, F; Odore, E; Quesnel, B; Raffoux, E; Rezaï, K; Riveiro, ME; Stathis, A; Thieblemont, C, 2016
)
0.43
" We here assessed the therapeutic efficacy of the orally bioavailable BRD4 inhibitor, MK-8628, in preclinical models of medulloblastoma."( Synergistic activity of BET inhibitor MK-8628 and PLK inhibitor Volasertib in preclinical models of medulloblastoma.
Althoff, K; Bei, Y; Deubzer, HE; Eggert, A; Garcia, HD; Han, Y; Henssen, AG; Künkele, A; Lindner, S; Lissat, A; Odersky, A; Schramm, A; Schulte, JH; Timme, N, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" While oral administration OTX015 in IMQ-treated mice reduced disease severity, ABBV075 equally decreased the symptoms and molecular and cellular severity markers at one-tenth of the minimal dosing required for OTX015."( A monocyte-keratinocyte-derived co-culture assay accurately identifies efficacies of BET inhibitors as therapeutic candidates for psoriasiform dermatitis.
Chong, J; Hsu, DK; Huynh, M; Hwang, ST; Mendoza, L; Shi, Z; Wu, X; Yamada, D, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organonitrogen heterocyclic compoundAny organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms.
organosulfur heterocyclic compound
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bromodomain-containing protein 4Homo sapiens (human)IC50 (µMol)0.04540.00040.40329.0500AID1229997; AID1229998; AID1289237; AID1359740; AID1387717; AID1387718; AID1460685; AID1464711; AID1534669; AID1584507; AID1605852; AID1605854; AID1605855; AID1615931; AID1727731; AID1727732; AID1845982; AID1859892; AID1859893; AID1881994; AID1881995
Bromodomain-containing protein 4Homo sapiens (human)Ki0.01100.00530.05330.3850AID1229997; AID1229998; AID1387717; AID1387718; AID1565541; AID1565542; AID1584507; AID1859870
Bromodomain-containing protein 2Homo sapiens (human)IC50 (µMol)0.06050.00090.53357.4000AID1387713; AID1387714; AID1460686; AID1845981
Bromodomain-containing protein 2Homo sapiens (human)Ki0.01460.00050.04470.2200AID1229999; AID1230000; AID1387713; AID1387714; AID1565545; AID1565546
Histone acetyltransferase p300Homo sapiens (human)IC50 (µMol)33.00000.26004.00008.5000AID1605856
Histone deacetylase 1Homo sapiens (human)IC50 (µMol)10.00000.00010.55439.9000AID1727729
Bromodomain-containing protein 3Homo sapiens (human)IC50 (µMol)0.06090.00030.28713.9620AID1387715; AID1387716; AID1460687; AID1845983
Bromodomain-containing protein 3Homo sapiens (human)Ki0.00820.00400.02230.0940AID1230001; AID1230002; AID1387715; AID1387716; AID1565543; AID1565544
Histone deacetylase 6Homo sapiens (human)IC50 (µMol)10.00000.00000.53769.9000AID1727730
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (163)

Processvia Protein(s)Taxonomy
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
neural tube closureBromodomain-containing protein 2Homo sapiens (human)
nucleosome assemblyBromodomain-containing protein 2Homo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain-containing protein 2Homo sapiens (human)
spermatogenesisBromodomain-containing protein 2Homo sapiens (human)
protein localization to chromatinBromodomain-containing protein 2Homo sapiens (human)
chromatin loopingBromodomain-containing protein 2Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone acetyltransferase p300Homo sapiens (human)
response to hypoxiaHistone acetyltransferase p300Homo sapiens (human)
somitogenesisHistone acetyltransferase p300Homo sapiens (human)
thigmotaxisHistone acetyltransferase p300Homo sapiens (human)
behavioral defense responseHistone acetyltransferase p300Homo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
regulation of glycolytic processHistone acetyltransferase p300Homo sapiens (human)
protein acetylationHistone acetyltransferase p300Homo sapiens (human)
internal protein amino acid acetylationHistone acetyltransferase p300Homo sapiens (human)
apoptotic processHistone acetyltransferase p300Homo sapiens (human)
canonical NF-kappaB signal transductionHistone acetyltransferase p300Homo sapiens (human)
nervous system developmentHistone acetyltransferase p300Homo sapiens (human)
heart developmentHistone acetyltransferase p300Homo sapiens (human)
skeletal muscle tissue developmentHistone acetyltransferase p300Homo sapiens (human)
learning or memoryHistone acetyltransferase p300Homo sapiens (human)
circadian rhythmHistone acetyltransferase p300Homo sapiens (human)
animal organ morphogenesisHistone acetyltransferase p300Homo sapiens (human)
regulation of autophagyHistone acetyltransferase p300Homo sapiens (human)
negative regulation of autophagyHistone acetyltransferase p300Homo sapiens (human)
macrophage derived foam cell differentiationHistone acetyltransferase p300Homo sapiens (human)
regulation of mitochondrion organizationHistone acetyltransferase p300Homo sapiens (human)
positive regulation of neuron projection developmentHistone acetyltransferase p300Homo sapiens (human)
N-terminal peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
internal peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine acetylationHistone acetyltransferase p300Homo sapiens (human)
B cell differentiationHistone acetyltransferase p300Homo sapiens (human)
platelet formationHistone acetyltransferase p300Homo sapiens (human)
lung developmentHistone acetyltransferase p300Homo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone acetyltransferase p300Homo sapiens (human)
protein destabilizationHistone acetyltransferase p300Homo sapiens (human)
cellular response to nutrient levelsHistone acetyltransferase p300Homo sapiens (human)
cellular response to UVHistone acetyltransferase p300Homo sapiens (human)
multicellular organism growthHistone acetyltransferase p300Homo sapiens (human)
megakaryocyte developmentHistone acetyltransferase p300Homo sapiens (human)
swimmingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of protein import into nucleusHistone acetyltransferase p300Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorHistone acetyltransferase p300Homo sapiens (human)
response to estrogenHistone acetyltransferase p300Homo sapiens (human)
positive regulation by host of viral transcriptionHistone acetyltransferase p300Homo sapiens (human)
fat cell differentiationHistone acetyltransferase p300Homo sapiens (human)
negative regulation of gluconeogenesisHistone acetyltransferase p300Homo sapiens (human)
transcription initiation-coupled chromatin remodelingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone acetyltransferase p300Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone acetyltransferase p300Homo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATHistone acetyltransferase p300Homo sapiens (human)
protein stabilizationHistone acetyltransferase p300Homo sapiens (human)
positive regulation of DNA-binding transcription factor activityHistone acetyltransferase p300Homo sapiens (human)
face morphogenesisHistone acetyltransferase p300Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine propionylationHistone acetyltransferase p300Homo sapiens (human)
cellular response to L-leucineHistone acetyltransferase p300Homo sapiens (human)
regulation of tubulin deacetylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine crotonylationHistone acetyltransferase p300Homo sapiens (human)
peptidyl-lysine butyrylationHistone acetyltransferase p300Homo sapiens (human)
regulation of cellular response to heatHistone acetyltransferase p300Homo sapiens (human)
regulation of signal transduction by p53 class mediatorHistone acetyltransferase p300Homo sapiens (human)
positive regulation of TORC1 signalingHistone acetyltransferase p300Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentHistone acetyltransferase p300Homo sapiens (human)
negative regulation of myotube differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
chromatin organizationHistone deacetylase 1Homo sapiens (human)
chromatin remodelingHistone deacetylase 1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone deacetylase 1Homo sapiens (human)
regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
protein deacetylationHistone deacetylase 1Homo sapiens (human)
endoderm developmentHistone deacetylase 1Homo sapiens (human)
positive regulation of cell population proliferationHistone deacetylase 1Homo sapiens (human)
epidermal cell differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
hippocampus developmentHistone deacetylase 1Homo sapiens (human)
neuron differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of cell migrationHistone deacetylase 1Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
circadian regulation of gene expressionHistone deacetylase 1Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusHistone deacetylase 1Homo sapiens (human)
odontogenesis of dentin-containing toothHistone deacetylase 1Homo sapiens (human)
regulation of cell fate specificationHistone deacetylase 1Homo sapiens (human)
embryonic digit morphogenesisHistone deacetylase 1Homo sapiens (human)
negative regulation of apoptotic processHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionHistone deacetylase 1Homo sapiens (human)
negative regulation by host of viral transcriptionHistone deacetylase 1Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone deacetylase 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIHistone deacetylase 1Homo sapiens (human)
positive regulation of smooth muscle cell proliferationHistone deacetylase 1Homo sapiens (human)
oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
positive regulation of oligodendrocyte differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of androgen receptor signaling pathwayHistone deacetylase 1Homo sapiens (human)
hair follicle placode formationHistone deacetylase 1Homo sapiens (human)
eyelid development in camera-type eyeHistone deacetylase 1Homo sapiens (human)
fungiform papilla formationHistone deacetylase 1Homo sapiens (human)
negative regulation of canonical Wnt signaling pathwayHistone deacetylase 1Homo sapiens (human)
negative regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
positive regulation of stem cell population maintenanceHistone deacetylase 1Homo sapiens (human)
regulation of stem cell differentiationHistone deacetylase 1Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayHistone deacetylase 1Homo sapiens (human)
heterochromatin formationHistone deacetylase 1Homo sapiens (human)
chromatin organizationBromodomain-containing protein 3Homo sapiens (human)
regulation of transcription by RNA polymerase IIBromodomain-containing protein 3Homo sapiens (human)
endodermal cell differentiationBromodomain-containing protein 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 3Homo sapiens (human)
protein localization to chromatinBromodomain-containing protein 3Homo sapiens (human)
polyamine deacetylationHistone deacetylase 6Homo sapiens (human)
spermidine deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of signaling receptor activityHistone deacetylase 6Homo sapiens (human)
protein polyubiquitinationHistone deacetylase 6Homo sapiens (human)
response to amphetamineHistone deacetylase 6Homo sapiens (human)
protein deacetylationHistone deacetylase 6Homo sapiens (human)
protein quality control for misfolded or incompletely synthesized proteinsHistone deacetylase 6Homo sapiens (human)
intracellular protein transportHistone deacetylase 6Homo sapiens (human)
autophagyHistone deacetylase 6Homo sapiens (human)
actin filament organizationHistone deacetylase 6Homo sapiens (human)
negative regulation of microtubule depolymerizationHistone deacetylase 6Homo sapiens (human)
regulation of autophagyHistone deacetylase 6Homo sapiens (human)
positive regulation of epithelial cell migrationHistone deacetylase 6Homo sapiens (human)
negative regulation of hydrogen peroxide metabolic processHistone deacetylase 6Homo sapiens (human)
regulation of macroautophagyHistone deacetylase 6Homo sapiens (human)
axonal transport of mitochondrionHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex assemblyHistone deacetylase 6Homo sapiens (human)
regulation of protein stabilityHistone deacetylase 6Homo sapiens (human)
protein destabilizationHistone deacetylase 6Homo sapiens (human)
lysosome localizationHistone deacetylase 6Homo sapiens (human)
protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylationHistone deacetylase 6Homo sapiens (human)
cellular response to heatHistone deacetylase 6Homo sapiens (human)
peptidyl-lysine deacetylationHistone deacetylase 6Homo sapiens (human)
response to immobilization stressHistone deacetylase 6Homo sapiens (human)
cellular response to topologically incorrect proteinHistone deacetylase 6Homo sapiens (human)
erythrocyte enucleationHistone deacetylase 6Homo sapiens (human)
ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathwayHistone deacetylase 6Homo sapiens (human)
negative regulation of protein-containing complex disassemblyHistone deacetylase 6Homo sapiens (human)
regulation of fat cell differentiationHistone deacetylase 6Homo sapiens (human)
negative regulation of gene expression, epigeneticHistone deacetylase 6Homo sapiens (human)
negative regulation of proteolysisHistone deacetylase 6Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone deacetylase 6Homo sapiens (human)
collateral sproutingHistone deacetylase 6Homo sapiens (human)
negative regulation of axon extension involved in axon guidanceHistone deacetylase 6Homo sapiens (human)
positive regulation of dendrite morphogenesisHistone deacetylase 6Homo sapiens (human)
negative regulation of oxidoreductase activityHistone deacetylase 6Homo sapiens (human)
response to corticosteroneHistone deacetylase 6Homo sapiens (human)
response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergicHistone deacetylase 6Homo sapiens (human)
cilium assemblyHistone deacetylase 6Homo sapiens (human)
regulation of microtubule-based movementHistone deacetylase 6Homo sapiens (human)
regulation of androgen receptor signaling pathwayHistone deacetylase 6Homo sapiens (human)
dendritic spine morphogenesisHistone deacetylase 6Homo sapiens (human)
cilium disassemblyHistone deacetylase 6Homo sapiens (human)
parkin-mediated stimulation of mitophagy in response to mitochondrial depolarizationHistone deacetylase 6Homo sapiens (human)
regulation of establishment of protein localizationHistone deacetylase 6Homo sapiens (human)
cellular response to hydrogen peroxideHistone deacetylase 6Homo sapiens (human)
aggresome assemblyHistone deacetylase 6Homo sapiens (human)
polyubiquitinated misfolded protein transportHistone deacetylase 6Homo sapiens (human)
response to growth factorHistone deacetylase 6Homo sapiens (human)
cellular response to misfolded proteinHistone deacetylase 6Homo sapiens (human)
cellular response to parathyroid hormone stimulusHistone deacetylase 6Homo sapiens (human)
response to dexamethasoneHistone deacetylase 6Homo sapiens (human)
tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of tubulin deacetylationHistone deacetylase 6Homo sapiens (human)
positive regulation of cellular response to oxidative stressHistone deacetylase 6Homo sapiens (human)
negative regulation of protein acetylationHistone deacetylase 6Homo sapiens (human)
regulation of autophagy of mitochondrionHistone deacetylase 6Homo sapiens (human)
positive regulation of cholangiocyte proliferationHistone deacetylase 6Homo sapiens (human)
negative regulation of aggrephagyHistone deacetylase 6Homo sapiens (human)
epigenetic regulation of gene expressionHistone deacetylase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (75)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 2Homo sapiens (human)
protein serine/threonine kinase activityBromodomain-containing protein 2Homo sapiens (human)
protein bindingBromodomain-containing protein 2Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 2Homo sapiens (human)
acetylation-dependent protein bindingBromodomain-containing protein 2Homo sapiens (human)
transcription coregulator bindingHistone acetyltransferase p300Homo sapiens (human)
transcription coactivator bindingHistone acetyltransferase p300Homo sapiens (human)
p53 bindingHistone acetyltransferase p300Homo sapiens (human)
DNA bindingHistone acetyltransferase p300Homo sapiens (human)
chromatin bindingHistone acetyltransferase p300Homo sapiens (human)
damaged DNA bindingHistone acetyltransferase p300Homo sapiens (human)
transcription coactivator activityHistone acetyltransferase p300Homo sapiens (human)
histone acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
lysine N-acetyltransferase activity, acting on acetyl phosphate as donorHistone acetyltransferase p300Homo sapiens (human)
protein bindingHistone acetyltransferase p300Homo sapiens (human)
beta-catenin bindingHistone acetyltransferase p300Homo sapiens (human)
zinc ion bindingHistone acetyltransferase p300Homo sapiens (human)
histone H3 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H4 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
nuclear receptor bindingHistone acetyltransferase p300Homo sapiens (human)
peptide N-acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H3K18 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H2B acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone H3K27 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
tau protein bindingHistone acetyltransferase p300Homo sapiens (human)
nuclear androgen receptor bindingHistone acetyltransferase p300Homo sapiens (human)
NF-kappaB bindingHistone acetyltransferase p300Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone acetyltransferase p300Homo sapiens (human)
peptide-lysine-N-acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
protein propionyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
pre-mRNA intronic bindingHistone acetyltransferase p300Homo sapiens (human)
STAT family protein bindingHistone acetyltransferase p300Homo sapiens (human)
peptide 2-hydroxyisobutyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone lactyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
acetylation-dependent protein bindingHistone acetyltransferase p300Homo sapiens (human)
peptide butyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone crotonyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
histone butyryltransferase activityHistone acetyltransferase p300Homo sapiens (human)
DNA-binding transcription factor bindingHistone acetyltransferase p300Homo sapiens (human)
histone H3K122 acetyltransferase activityHistone acetyltransferase p300Homo sapiens (human)
chromatin DNA bindingHistone acetyltransferase p300Homo sapiens (human)
nucleosomal DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
core promoter sequence-specific DNA bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 1Homo sapiens (human)
p53 bindingHistone deacetylase 1Homo sapiens (human)
transcription corepressor activityHistone deacetylase 1Homo sapiens (human)
histone deacetylase activityHistone deacetylase 1Homo sapiens (human)
protein bindingHistone deacetylase 1Homo sapiens (human)
enzyme bindingHistone deacetylase 1Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 1Homo sapiens (human)
Krueppel-associated box domain bindingHistone deacetylase 1Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 1Homo sapiens (human)
NF-kappaB bindingHistone deacetylase 1Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
E-box bindingHistone deacetylase 1Homo sapiens (human)
DNA-binding transcription factor bindingHistone deacetylase 1Homo sapiens (human)
histone decrotonylase activityHistone deacetylase 1Homo sapiens (human)
promoter-specific chromatin bindingHistone deacetylase 1Homo sapiens (human)
chromatin bindingBromodomain-containing protein 3Homo sapiens (human)
protein bindingBromodomain-containing protein 3Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 3Homo sapiens (human)
lncRNA bindingBromodomain-containing protein 3Homo sapiens (human)
molecular condensate scaffold activityBromodomain-containing protein 3Homo sapiens (human)
acetylspermidine deacetylase activityHistone deacetylase 6Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingHistone deacetylase 6Homo sapiens (human)
transcription corepressor bindingHistone deacetylase 6Homo sapiens (human)
actin bindingHistone deacetylase 6Homo sapiens (human)
histone deacetylase activityHistone deacetylase 6Homo sapiens (human)
protein bindingHistone deacetylase 6Homo sapiens (human)
beta-catenin bindingHistone deacetylase 6Homo sapiens (human)
microtubule bindingHistone deacetylase 6Homo sapiens (human)
zinc ion bindingHistone deacetylase 6Homo sapiens (human)
enzyme bindingHistone deacetylase 6Homo sapiens (human)
polyubiquitin modification-dependent protein bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin protein ligase bindingHistone deacetylase 6Homo sapiens (human)
protein lysine deacetylase activityHistone deacetylase 6Homo sapiens (human)
histone deacetylase bindingHistone deacetylase 6Homo sapiens (human)
tubulin deacetylase activityHistone deacetylase 6Homo sapiens (human)
alpha-tubulin bindingHistone deacetylase 6Homo sapiens (human)
ubiquitin bindingHistone deacetylase 6Homo sapiens (human)
tau protein bindingHistone deacetylase 6Homo sapiens (human)
beta-tubulin bindingHistone deacetylase 6Homo sapiens (human)
misfolded protein bindingHistone deacetylase 6Homo sapiens (human)
Hsp90 protein bindingHistone deacetylase 6Homo sapiens (human)
dynein complex bindingHistone deacetylase 6Homo sapiens (human)
transcription factor bindingHistone deacetylase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
chromatinBromodomain-containing protein 2Homo sapiens (human)
nucleusBromodomain-containing protein 2Homo sapiens (human)
nucleoplasmBromodomain-containing protein 2Homo sapiens (human)
cytoplasmBromodomain-containing protein 2Homo sapiens (human)
nuclear speckBromodomain-containing protein 2Homo sapiens (human)
cytoplasmHistone acetyltransferase p300Homo sapiens (human)
cytosolHistone acetyltransferase p300Homo sapiens (human)
nucleusHistone acetyltransferase p300Homo sapiens (human)
nucleoplasmHistone acetyltransferase p300Homo sapiens (human)
cytosolHistone acetyltransferase p300Homo sapiens (human)
chromatinHistone acetyltransferase p300Homo sapiens (human)
protein-DNA complexHistone acetyltransferase p300Homo sapiens (human)
transcription regulator complexHistone acetyltransferase p300Homo sapiens (human)
histone acetyltransferase complexHistone acetyltransferase p300Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleoplasmHistone deacetylase 1Homo sapiens (human)
cytoplasmHistone deacetylase 1Homo sapiens (human)
cytosolHistone deacetylase 1Homo sapiens (human)
NuRD complexHistone deacetylase 1Homo sapiens (human)
neuronal cell bodyHistone deacetylase 1Homo sapiens (human)
Sin3-type complexHistone deacetylase 1Homo sapiens (human)
histone deacetylase complexHistone deacetylase 1Homo sapiens (human)
chromatinHistone deacetylase 1Homo sapiens (human)
heterochromatinHistone deacetylase 1Homo sapiens (human)
transcription repressor complexHistone deacetylase 1Homo sapiens (human)
protein-containing complexHistone deacetylase 1Homo sapiens (human)
nucleusHistone deacetylase 1Homo sapiens (human)
nucleusBromodomain-containing protein 3Homo sapiens (human)
chromatinBromodomain-containing protein 3Homo sapiens (human)
nucleusHistone deacetylase 6Homo sapiens (human)
nucleoplasmHistone deacetylase 6Homo sapiens (human)
cytoplasmHistone deacetylase 6Homo sapiens (human)
multivesicular bodyHistone deacetylase 6Homo sapiens (human)
centrosomeHistone deacetylase 6Homo sapiens (human)
cytosolHistone deacetylase 6Homo sapiens (human)
microtubuleHistone deacetylase 6Homo sapiens (human)
caveolaHistone deacetylase 6Homo sapiens (human)
inclusion bodyHistone deacetylase 6Homo sapiens (human)
aggresomeHistone deacetylase 6Homo sapiens (human)
axonHistone deacetylase 6Homo sapiens (human)
dendriteHistone deacetylase 6Homo sapiens (human)
cell leading edgeHistone deacetylase 6Homo sapiens (human)
ciliary basal bodyHistone deacetylase 6Homo sapiens (human)
perikaryonHistone deacetylase 6Homo sapiens (human)
perinuclear region of cytoplasmHistone deacetylase 6Homo sapiens (human)
axon cytoplasmHistone deacetylase 6Homo sapiens (human)
histone deacetylase complexHistone deacetylase 6Homo sapiens (human)
microtubule associated complexHistone deacetylase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (122)

Assay IDTitleYearJournalArticle
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1827529Cytotoxicity against human MOLM-14 cells assessed as reduction in cell viability incubated for 72 hrs2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.
AID1881961Antiproliferative activity against human HL-60(TB) cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-Glo assay
AID1356112Antitumor activity against human MDA-MB-231 cells xenografted in SCID mouse assessed as tumor growth inhibition at 50 mg/kg administered via oral gavage measured on day 442018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
AID1387718Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
AID1616013Induction of apoptosis in human MV4-11 cells assessed as reduction in c-IAP2 level after 24 hrs by Western blot analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1230002Displacement of FAM-labeled ZBA248 from BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1827530Downregulation of Myc expression in human MOLM-14 cells incubated for 2 hrs by RT-PCR analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.
AID1846026Antitumor activity against human UW228 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1565583Downregulation of ARID5B in human HepG2 cells after 4 hrs by qRT-PCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1881994Inhibition of BRD4 BD1 (unknown origin) by fluorescence based assay
AID1727729Inhibition of HDAC1 (unknown origin) by fluorescence based assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1727730Inhibition of HDAC6 (unknown origin) by fluorescence based assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1565547Selectivity index, ratio of Ki for human recombinant BRD4 BD1 (44 to 168 residues) to Ki for human recombinant BRD4 BD2 (333 to 460 residues)2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1460687Inhibition of acetylated H4 binding to BRD3 (unknown origin)2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Drug Discovery Targeting Bromodomain-Containing Protein 4.
AID1464711Inhibition of BRD4 BD1-BD2 (unknown origin) using tetraacetylated histone peptide as substrate after 2 hrs by alphascreen assay2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
AID1615979Antiproliferative activity against human MV4-11 cells after 72 hrs by CCK8 or SRB assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1616000Induction of apoptosis in human MV4-11 cells assessed as increase in cleaved caspase-9 level after 24 hrs by Western blot analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1605853Binding affinity to N-terminal His6-tagged BRD4 bromodomain 1 (49 to 170 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) assessed as change in melting temperature at 1:100 molar ratio by SYPRO orange dye based fluorescence thermal shif2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1727731Inhibition of His-tagged BRD4 bromodomain 1 (unknown origin) using [Lys (5,8,12,16) Ac] H4(1-21) as substrate by fluorescence based assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1881962Antiproliferative activity against human NCI-H522 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-Glo assay
AID1832809Anticancer activity against human K562 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1832807Anticancer activity against human TALL-1 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1565587Decrease in c-Myc protein expression in human MV4-11 cells incubated for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1845981Inhibition of BRD2 (unknown origin)2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1881995Inhibition of BRD4 BD2 (unknown origin) by fluorescence based assay
AID1230001Displacement of FAM-labeled ZBA248 from BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1605887Antiproliferative activity against human Kasumi-1 cells assessed as reduction in cell viability measured after 72 hrs by Celltitre-glo luminescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1727732Inhibition of His-tagged BRD4 bromodomain 2 (unknown origin) using [Lys (5,8,12,16) Ac] H4(1-21) as substrate by fluorescence based assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1605858Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability measured after 72 hrs by Celltitre-glo luminescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1565584Downregulation of G6PC in human HepG2 cells after 4 hrs by qRT-PCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1229998Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1605900Cell cycle arrest in human MV4-11 cells assessed as increase in accumulation at G1-phase at 125 nM measured after 24 hrs by propidium iodide staining based flow cytometry2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1881967Antiproliferative activity against human MDA-MB-468 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-Glo assay
AID1727745Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation at G0/G1 phase after 24 hrs by flow cytometry2021European journal of medicinal chemistry, Jan-01, Volume: 209Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1565546Binding affinity to human recombinant BRD2 BD2 (349 to 460 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1499147Antitumor activity against human MM1S cells xenografted in Balb/c nude mouse assessed as tumor volume at 50 mg/kg, po administered daily for 14 days relative to control2017European journal of medicinal chemistry, Sep-08, Volume: 137Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
AID1881963Antiproliferative activity against human HCT-15 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-Glo assay
AID1827534Inhibition of IFNgamma induced MHC-1 expression in human K562 cells treated for 48 hrs by flow cytometric analysis2022Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7
CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.
AID1615980Antiproliferative activity against human TY82 cells after 72 hrs by CCK8 or SRB assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1387714Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD2 bromodomain 2 (349 to 460 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
AID1859893Inhibition of BRD4 BD2 (unknown origin) fluorescence polarization method2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.
AID1289237Inhibition of BRD4 bromodomain 1 (unknown origin)2016Journal of medicinal chemistry, Feb-25, Volume: 59, Issue:4
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.
AID1615996Inhibition of BRD4 in human MV4-11 cells assessed as reduction in c-Myc mRNA level at 10 to 100 nM after 24 hrs by real time qPCR analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1846024Antitumor activity against human Daoy cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1881966Antiproliferative activity against human CAKI-1 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-Glo assay
AID1615997Induction of apoptosis in human MV4-11 cells after 24 hrs by Annexin V staining based assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1859892Inhibition of BRD4 BD1 (unknown origin) fluorescence polarization method2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.
AID1565572Upregulation of p21 mRNA expression in human MV4-11 cells after 24 hrs by qRT-PCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1832810Anticancer activity against human HAL-01 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1565571Downregulation of cMyc mRNA expression in human MV4-11 cells after 24 hrs by qRT-PCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1584507Binding affinity to human BRD4 BD1 (44 to 168 residues) by fluorescence polarization assay2018Journal of medicinal chemistry, Aug-09, Volume: 61, Issue:15
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
AID1605898Inhibition of BRD4 in human MV4-11 cells assessed as reduction in CDK6 mRNA level at 31.25 to 125 nM measured after 6 hrs by SYBR green dye based RT-qPCR analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1460685Inhibition of acetylated H4 binding to BRD4 (unknown origin)2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Drug Discovery Targeting Bromodomain-Containing Protein 4.
AID1832808Anticancer activity against human HL-60 cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1859887Protection against LPS-induced sepsis in C57BL/6 mouse model assessed as reduction in hypothermia at 10 mg/kg, ip qd administered for 3 days followed by LPS stimulation for 12 hrs and measured every 1 hr by digital thermometer2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.
AID1615999Induction of apoptosis in human MV4-11 cells assessed as increase in cleaved caspase-8 level after 24 hrs by Western blot analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1881964Antiproliferative activity against human SNB-75 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-Glo assay
AID1565586Selectivity index, ratio of Ki for human recombinant BRD3 BD2 (306 to 417 residues) to Ki for human recombinant BRD3 BD1 (24 to 144 residues)2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1230000Displacement of FAM-labeled ZBA248 from BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1359740Inhibition of BRD4 bromodomain-1 (unknown origin) by AlphaScreen assay2018European journal of medicinal chemistry, May-25, Volume: 152Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
AID1387715Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD3 bromodomain 1 (24 to 144 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
AID1615995Inhibition of BRD4 in human MV4-11 cells assessed as reduction in c-Myc expression at 10 nM after 24 hrs by Western blot analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1387717Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
AID1229997Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1565588Increase in p21 protein expression in human MV4-11 cells incubated for 24 hrs by western blot analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1605856Inhibition of MSGRGK(Ac)-GGK(Ac)GLGK(Ac)GGAKRHR-biotin binding to EP300 (1040 to 1160 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) by Alphascreen assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1460686Inhibition of acetylated H4 binding to BRD2 (unknown origin)2017Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11
Drug Discovery Targeting Bromodomain-Containing Protein 4.
AID1605854Inhibition of SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVGG-K-Biotin binding to N-terminal His6-tagged BRD4 bromodomain 1 (49 to 170 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) preincubated for 15 mins followed by biotin-labeled 2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1565545Binding affinity to human recombinant BRD2 BD1 (72 to 205 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1464712Antiproliferative activity against human TY82 cells2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
AID1565541Binding affinity to human recombinant BRD4 BD1 (44 to 168 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1846023Antitumor activity against human HD-MB03 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1464713Antiproliferative activity against human THP1 cells2017Bioorganic & medicinal chemistry letters, 10-15, Volume: 27, Issue:20
Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
AID1616065Antitumor activity against human MV4-11 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 100 mg/kg, po administered once daily and measured twice a week by caliper method relative to control2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1229999Displacement of FAM-labeled ZBA248 from BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay2015Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12
Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
AID1727733Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay2021European journal of medicinal chemistry, Jan-01, Volume: 209Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes.
AID1605889Antiproliferative activity against human MM1S cells assessed as reduction in cell viability measured after 72 hrs by Celltitre-glo luminescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1605888Antiproliferative activity against human RS4:11 cells assessed as reduction in cell viability measured after 72 hrs by Celltitre-glo luminescence assay2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1616063Antitumor activity against human MV4-11 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 50 mg/kg, po administered once daily and measured twice a week by caliper method relative to control2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1605852Inhibition of BRD4 (unknown origin)2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1387713Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD2 bromodomain 1 (72 to 205 residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
AID1605896Inhibition of BRD4 in human MV4-11 cells assessed as reduction in c-Myc mRNA level at 31.25 to 125 nM measured after 6 hrs by SYBR green dye based RT-qPCR analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1859875Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 10 uM preincubated for 2 hrs followed by LPS stimulation and measured after 22 hrs by Griess reagent-based assay relative to control2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.
AID1859874Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production at 5 uM preincubated for 2 hrs followed by LPS stimulation and measured after 22 hrs by Griess reagent-based assay relative to control2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.
AID1534669Inhibition of recombinant full length human N-terminal His6-tagged BRD4 (2 to 1362 residues) expressed in baculovirus infected insect cells using histone H4 peptide as substrate by alpha screen assay2019European journal of medicinal chemistry, Feb-01, Volume: 163Rational design of 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol derivatives as novel bromodomain-containing protein 4 inhibitors.
AID1565549Selectivity index, ratio of Ki for human recombinant BRD2 BD1 (72 to 205 residues) to Ki for human recombinant BRD2 BD2 (349 to 460 residues)2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1605897Inhibition of BRD4 in human MV4-11 cells assessed as reduction in BCL2 mRNA level at 31.25 to 125 nM measured after 6 hrs by SYBR green dye based RT-qPCR analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1616012Induction of apoptosis in human MV4-11 cells assessed as reduction in c-IAP1 level after 24 hrs by Western blot analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1845982Inhibition of BRD4 (unknown origin)2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1832806Anticancer activity against human HPBALL cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1565540Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 4 days by CCK8 assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1605895Inhibition of BRD4 in human MV4-11 cells assessed as reduction in c-Myc expression at 500 nM measured after 6 to 24 hrs by Western blot analysis2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1387716Inhibition of FAM-labeled ZBA248 binding to recombinant N-terminal His6-tagged BRD3 bromodomain 2 (306 to 417residues) (unknown origin) expressed in Escherichia coli Rosetta2 DE3 after 30 mins by fluorescence polarization assay2018Journal of medicinal chemistry, 01-25, Volume: 61, Issue:2
Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression.
AID1615932Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 or SRB assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1565543Binding affinity to human recombinant BRD3 BD1 (24 to 144 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1565544Binding affinity to human recombinant BRD3 BD2 (306 to 417 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1615931Displacement of 5-FITC labelled (+)-JQ1 from His6-tagged human BRD4 bromodomain 1 expressed in Escherichia coli BL21(DE3) )-codon plus-RIL cells incubated for 4 hrs in dark condition by fluorescence anisotropy binding assay2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1832811Anticancer activity against human REH cells assessed as cell growth inhibition by CellTiter-Glo luminescent assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
4-Acyl Pyrrole Capped HDAC Inhibitors: A New Scaffold for Hybrid Inhibitors of BET Proteins and Histone Deacetylases as Antileukemia Drug Leads.
AID1859870Inhibition of BRD4 BD1 (unknown origin) using FAM-labeled JQ-1 as fluorescent substrate assessed as inhibition constant incubated for 30 mins by competitive fluorescence polarization method2022European journal of medicinal chemistry, Aug-05, Volume: 238Discovery of 2-((2-methylbenzyl)thio)-6-oxo-4-(3,4,5-trimethoxyphenyl)-1,6-dihydropyrimidine-5-carbonitrile as a novel and effective bromodomain and extra-terminal (BET) inhibitor for the treatment of sepsis.
AID1845983Inhibition of BRD3 (unknown origin)2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1565548Antiproliferative activity against human MM1S cells assessed as cell growth inhibition after 4 days by CCK8 assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1881988Antitumor activity against human MV4-11 cells xenografted BALB/c nude mouse model assessed as tumor growth inhibition at 20 mg/kg, po QD administered for 28 consecutive days
AID1565542Binding affinity to human recombinant BRD4 BD2 (333 to 460 residues) by fluorescence polarization assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1359741Antiproliferative activity against human LNCAP cells2018European journal of medicinal chemistry, May-25, Volume: 152Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
AID1846025Antitumor activity against human ONS-76 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo luminescent assay2021European journal of medicinal chemistry, Apr-05, Volume: 215Medulloblastoma drugs in development: Current leads, trials and drawbacks.
AID1565585Downregulation of NRIH4 in human HepG2 cells after 4 hrs by qRT-PCR analysis2019European journal of medicinal chemistry, Nov-15, Volume: 182Discovery, structural insight, and bioactivities of BY27 as a selective inhibitor of the second bromodomains of BET proteins.
AID1605913Antitumor activity against human MV4-11 cells xenografted in mouse assessed as tumor growth inhibition at 50 mg/kg, po administered for 28 days and measured every 2 to 3 days during compound dosing relative to control2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1881965Antiproliferative activity against human UACC-62 cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-Glo assay
AID1616011Induction of apoptosis in human MV4-11 cells assessed as reduction in XIAP level after 24 hrs by Western blot analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1605855Inhibition of SGRG-K(Ac)-GG-K(Ac)-GLG-K(Ac)-GGA-K(Ac)-RHRKVGG-K-Biotin binding to N-terminal His6-tagged BRD4 bromodomain 2 (344 to 455 residues) (unknown origin) expressed in Escherichia coli BL21 (DE3) preincubated for 15 mins followed by biotin-labeled2020Journal of medicinal chemistry, 04-23, Volume: 63, Issue:8
Discovery of 8-Methyl-pyrrolo[1,2-
AID1356114Antitumor activity against human RS4:11 cells xenografted in SCID mouse assessed as tumor growth inhibition at 50 mg/kg administered via oral gavage measured on day 352018Journal of medicinal chemistry, 07-26, Volume: 61, Issue:14
Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
AID1616015Induction of cell cycle arrest in human RKO cells assessed as increase in accumulation at G1 phase at 100 nM after 24 hrs by propidium iodide staining based flow cytometric analysis2019Journal of medicinal chemistry, 09-26, Volume: 62, Issue:18
Structure-Based Discovery and Development of a Series of Potent and Selective Bromodomain and Extra-Terminal Protein Inhibitors.
AID1347414qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347415qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: tertiary screen by RT-qPCR2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's51 (69.86)24.3611
2020's22 (30.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.22 (24.57)
Research Supply Index4.36 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (5.48%)5.53%
Reviews2 (2.74%)6.00%
Case Studies2 (2.74%)4.05%
Observational0 (0.00%)0.25%
Other65 (89.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]